12 month contract for Sussex CDC pilot extension

Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement, this information is now considered to be in the public domain.

Feedback plc

Feedback awarded twelve month contract for pilot extension in Sussex Community Diagnostic Centre

·      £450,000 contract to cover a 12 month extension of initial pilot phase of Sussex Health and Care Partnership Integrated Care System ("Sussex ICS") development programme with Queen Victoria Hospital ("QVH").

·      Follows on from the previously announced memorandum of understanding ("MOU") to embark on a pilot scheme, providing services with the exemplar Sussex ICS Community Diagnostic Centre ("CDC") site at QVH.

·      The contract enables extension of the current pilot programme whilst QVH embarks on a formal procurement process for a solution in the long term. This procurement is anticipated to be completed in March 2023. The Company will submit a bid in this subsequent procurement.

London, 6th September 2022: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist clinical infrastructure company, announces that it has been awarded a twelve-month contract to provide its CDC solution in order to facilitate an extension of the current CDC pilot in Sussex to further GP practices and to enable the adoption of further clinical pathways. The discounted contract is valued at £450,000 and covers the period from 31^st March 2022 when the pilot MOU formally ended. The contract will run until 31^st March 2023 by which point QVH expect to have concluded a formal procurement for the next phase of the CDC programme rollout, as is required by NHS procurement policies. Feedback intends to submit a bid in this subsequent procurement phase.

The contract comes as the first live patients go through the CDC pilot as a result of the MOU signed with the Sussex ICS in October 2021, which was to embark on a pilot scheme to establish symptom-based pathway models for CDC services using Feedback's digital infrastructure solutions Bleepa and CareLocker. QVH in Sussex is one of the UK's exemplar CDC sites and the first to deliver end-to-end symptom-based pathways through the CDC programme. As previously announced, the deployment of Feedback's product suite in the Sussex ICS is intended to be used as a blueprint model for future CDC digital infrastructure models across the UK.

Bleepa's patient-centric design enables clinicians to collaborate on a patient-by-patient basis across geography, with the clinical discussion forming an auditable record for the patient episode that is subsequently shared with all stakeholders. CareLocker's ability to integrate with multiple clinical systems and centralise data around an individual patient means that all the diagnostic results can be seen in one place across all provider groups, ensuring that relevant data can be collected from multiple clinical settings, travels with the patient and is always available to clinicians.

Dr Tom Oakley, CEO of Feedback, said: "QVH and the broader Sussex team have been great partners in delivering this end-to-end clinical solution. This contract recognises the initial stage of our work together and enables us to proceed to a more formal working arrangement, pending a successful procurement exercise.

Together we have demonstrated that CDCs can be used to successfully deliver cross-provider symptom-based diagnostic pathways that transform the patient journey within the NHS and we expect to be able to show a meaningful impact on patient waiting lists as a result. ICSs need to adopt a symptom-based pathway approach to CDCs if they are going to deliver the expected impact on cancer and elective care waiting times. This pilot is the first example in the country of how this can be delivered and our digital infrastructure is an essential component of delivering it."

Further information on Feedback and its products can be found on the Company's website: https://fbkmed.com/feedback-plc/reports-and-presentations/

-Ends-

Enquiries:

About Feedback

Feedback plc helps clinical teams to make better decisions faster for patients. We design products that enhance clinician access to patient data and to their colleagues. Our unique approach centres around individual patient episodes, into which we pull relevant clinical data from hospital systems and around which we build remote clinical teams for collaboration. As a result, we produce a digital infrastructure that makes patient data available to clinicians in multiple settings, in a format that enables them to meaningfully interact with it, providing flexibility to clinicians and free movement of patients between provider settings - clinicians can practice from anywhere and patients can attend any care provider for investigation and treatment.

Our products Bleepa and CareLocker work together to deliver unparalleled value to our customers. Bleepa is our application layer and sits on top of CareLocker as our data layer. Bleepa is a clinician facing platform that displays clinical results from a patient's CareLocker at a certified and regulated quality, that is suitable for clinical use and enables dialogue on a patient-by-patient basis with colleagues through a secure, auditable chat interface that links back to the patient medical record. CareLocker provides an alternative to traditional system/cloud storage and stores clinical data at an individual patient level, wrapping relevant clinical data around the specific patient, ensuring that data is always linked to the patient and is available to them and any care setting that they attend - it is a federated data architecture with the patient as the tenant.

The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based revenue model is expected to provide increasing levels of visibility as the Company grows its customer base.